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ABSTRACT41
The use of vitreous humor and pericardial fluid as alternative matrices to blood and plasma in the field of 42
forensic toxicology is described to quantitate low levels of Salvinorin A using ethion as internal standard.43
The method was optimized and fully validated using international accepted guidelines. The developed 44
methodology utilizes a solid phase extraction procedure coupled to gas chromatography mass 45
spectrometry operated in the selected ion monitoring mode. The method was linear in the range of 5.0 to 46
100 ng/mL with determination coefficients higher than 0.99 in 100 µL of vitreous humor and in 250 µL47
of each matrix pericardial fluid, whole blood and plasma. The limits of detection and quantitation were 48
experimentally determined as 5.0 ng/mL, intra-day precision, intermediate precision and accuracy were in 49
conformity with the criteria normally accepted in bioanalytical method validation. The sample cleanup 50
step presented mean efficiencies between 80 and 106% in the different biological specimens analysed. 51
According to the low volumes of samples used, and the low limits achieved using a single quadrupole 52
mass spectrometer, which is available in most laboratories, we can conclude that the validated 53
methodology is sensitive and simple and is suitable for the application in forensic toxicology laboratories 54
for the routine analysis of Salvinorin A in both conventional and unconventional biological samples.55
56
Keywords: Salvinorin A; Biological specimens; SPE; GC-MS-EI57
58
1. Introduction59
In recent years, the number of stores called “smartshops” has increased, especially in major urban 60
centres. In these shops products with psychoactive effects, commonly named “legal highs”, are freely 61
sold. Salvia divinorum is a plant with hallucinogenic effects that is among the substances sold in those 62
stores. However, it should be kept in mind that “natural” and “legal” do not mean free from danger to 63
health. Another problem related to this type of products refers to is fact that there are no sufficient data or 64
studies on the long-term effects of these substances on the human body, which might expose its 65
consumers to physical and psychological risks. According to the 2012 annual report of the European 66
Monitoring Centre for Drugs and Drug Addiction [1], Salvia divinorum is among the three natural “legal 67
highs” most frequently available at online shops.68
Salvia divinorum is a plant member of the Lamiaceae mint family that has been used for centuries by the 69
Mazatec in Oaxaca, Mexico, in traditional religious practices. Its main active metabolite is the 70
neoclerodane diterpene Salvinorin A and the only known psychoactive terpenoid of Salvia divinorum [1, 71
2]. Salvinorin A is a potent and selective k-opioid receptor agonist with no affinity for the 5-HT2A, the72
principal molecular target responsible for the action of classical hallucinogens (DOB, LSD, psilocybin, 73
N,N-dimethyltryptamine, mescaline and ketamine) [3-6]. This plant is growing in popularity in Portugal 74
and many other countries as a powerful hallucinogenic recreational drug. Its acquisition is legal in most 75
states of USA and several European countries, and its main consumers are adolescents and young adults. 76
Its availability has been rapidly increasing, due to the spreading of the “smartshops” and also to its easy 77
purchase in Internet websites. Since the beginning of this year, several Portuguese hospitals have notified 78
the hospitalization of patients with symptoms including complete loss of contact with reality, 79
uncontrollable laughter, short-term loss of consciousness, headaches, panic crisis, depression, tremor, 80
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nausea, hearing voices, unrealistic visions, sense of death, excitement, increased heart rhythm, potential 81
self injuries without feeling pain, and, sometimes, coma, after the consumption of Salvia divinorum [7]. 82
However, no published data is available concerning reported cases of salvinorin-related deaths. 83
Nevertheless, postmortem analysis may be relevant, for instance in those cases where an individual died84
under the influence of the drug, but whose death was not directly caused by it.85
This drug can be taken by smoking, chewing or drinking in a tea [8]. The active ingredient, Salvinorin A, 86
has been reported to induce intense hallucinations in humans, with a typical duration of action between 87
several minutes to an hour [3-11]. Mouth absorption is reduced and it is also poorly absorbed in the 88
gastrointestinal tract. When smoked, the effects of salvinorin A are much more pronounced, inhaled doses89
of 200-500 µg produce profound hallucinations [3-9, 12-13]. The complete metabolism of Salvinorin A 90
is not well known [14]. Pharmacokinetic studies showed a relatively fast elimination of Salvinorin A, with 91
a half-life (t1/2) of 75 min and a clearance (Cl/F) of 26 L/h/kg [15]. Concerning metabolism, studies 92
using rhesus monkey blood have shown that Salvinorin A is deacetylated to Salvinorin B, a compound 93
with no significant affinity to k-opioid receptors [16-17].94
95
In 2005, two studies were published, in which Salvinorin A was determined in biological fluids: the first 96
one was in human plasma, urine, saliva and sweat using liquid-liquid extraction coupled with gas 97
chromatography-mass spectrometry [13]; and the second was in human and rhesus monkey plasma, 98
human urine and in rhesus monkey cerebrospinal fluid, utilizing solid-phase extraction and high 99
performance liquid chromatography – atmospheric pressure chemical ionization mass spectrometry [10]. 100
Later, in 2008, Salvinorin A was studied in human urine and blood samples by solid-phase extraction and 101
liquid chromatography - electrospray ionization mass spectrometry [18]. Finally, in 2012 and 2013, this 102
compound was analysed in human urine using either liquid-liquid extraction or solid-phase 103
microextraction with comprehensive two – dimensional gas chromatography-time of flight mass 104
spectrometry [19] and microextraction in packed syringe with gas chromatography-mass spectrometry105
[20]. As we can see, there are limited data and a few analytical methods available in the scientific 106
literature for the determination of this compound in biological fluids, and data related to concentrations107
obtained in authentic samples are scarce.108
The identification and quantitation of drugs in biological specimens is one of the most important 109
objectives in forensic toxicology because in some postmortem cases, neither blood nor urine can be 110
collected due to severe exsanguination or advanced putrefaction. In these situations vitreous humor and 111
pericardial fluid can be useful. However, these biological matrices should not be seen as substitutes for 112
blood but as complementary specimens that can provide important information about the intake of toxic 113
substances. Vitreous humor is mainly composed of water (99%) and is anatomically protected from 114
contamination and bacterial degradation due to the protected environment inside the ocular globe. A 115
disadvantage of this matrix is the limited volume that can be collected during autopsy (1-2 mL per eye) 116
[21]. Pericardial fluid, has several advantages as a matrix in forensic toxicology, such as the high volume 117
that can be collected during autopsy (about 10 mL). This specimen is easily obtained from a closed cavity 118
(pericardial cavity), and it is well protected from contamination and by postmortem changes [22-23]. One 119
the other hand, sufficient amounts of this matrix can be obtained even from a completely exsanguinated120
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body. A study realized with fresh cadavers demonstrated that there is a good correlation between 121
pericardial fluid and blood of the femoral vein, suggesting that drug concentration in pericardial fluid is 122
useful for estimation of intoxication degree [24-28]. However, care should be taken, since pericardial 123
fluid can be contaminated by postmortem diffusion, if a large amount of a drug is present in the stomach 124
[29].125
The aim of this study was to develop and validate a sensitive and specific gas chromatography mass 126
spectrometry (GC-MS-EI) method to determine Salvinorin A in pericardial fluid (PF), vitreous humor 127
(VH), whole blood (BL) and plasma (PL) matrices, suitable for the application in forensic toxicology128
routine analysis.129
130
2. Materials and methods131
132
2.1. Reagents and standards133
The analytical standards of Salvinorin A and ethion (internal standard) were purchased from LCG 134
Promochem (Barcelona, Spain) and Sigma-Aldrich (St Louis, USA), respectively.135
Acetonitrile (LiChrosolv®), methanol (LiChrosolv®), 2-propanol, dichloromethane, n-hexane and 136
potassium dihydrogen phosphate, all of analytical grade, were obtained from Merck (Darmstadt, 137
Germany).138
Oasis® HLB (3mL, 60 mg) extraction cartridges were purchased from Waters (Milford, MA, USA).139
A stock solution of Salvinorin A (1 mg/mL) was prepared in acetonitrile. Working solutions at 50, 5, 0.5 140
and 0.05 µg/mL were prepared by proper dilution of the stock solution with acetonitrile. Additional 141
working solutions, at the same concentrations, were prepared to be used in the quality control samples. A 142
working solution of the internal standard (ethion) at 2 µg/mL was prepared in methanol. All solutions 143
were protected from light and stored at a temperature between 2 and 8ºC.144
Potassium dihydrogen phosphate 0.1 M was prepared by dissolving 13.61 g of potassium dihydrogen 145
phosphate in deionized water, obtaining a final volume of 1000 mL of buffer solution.146
147
2.2. Biological samples148
For calibration purposes and validation experiments, blank blood and plasma samples were obtained from 149
a local blood bank. Vitreous humor,  pericardial fluid and postmortem blank blood were collected during 150
autopsies performed at the Medico-Legal Office of the National Institute of Legal Medicine and Forensic 151
Sciences, Centre Branch, Aveiro, Portugal. These samples were free of drugs of abuse, as they were 152
screened before being used for both calibrators and control samples. All samples were stored at -15 ºC 153
before analysis.154
155
2.3. Gas chromatographic-mass spectrometric conditions156
Chromatographic analysis was performed using a HP 6890 gas chromatograph (Hewlett-Packard, 157
Waldbronn, Germany) equipped with a 5973 mass-selective detector (Hewlett-Packard, Waldbronn, 158
Germany) and a capillary column (30m x 0.32mm I.D., 0.25mm film thickness) with 5% 159
phenylmethylsiloxane (HP-5 MS) supplied by J&W Scientific (Folsom, CA, USA).160
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The gas chromatograph oven temperature program was as follows: 70 ºC held for 3 min, which was 161
increased by 30 ºC/min to 300 ºC and held for 6 min. The splitless injection mode (2 µL) was used with a 162
constant flow rate (1.2 mL/min) of highly purified helium. The mass spectrometer was operated with a 163
filament current of 300 µA at electron energy of 70 eV in the electron ionization (EI) mode. The 164
temperatures of the injection port and detector were set at 250 and 280 ºC, respectively. Quantitation was 165
done in the selected ion monitoring (SIM) mode, and the ions were monitored at m/z 318, 359, 404 and 166
432 (quantitation ion) for Salvinorin A, and only one ion was monitored at m/z 231 for the internal 167
standard, ethion. A full-scan mass spectra of Salvinorin A and ethion, as well as their chemical structures168
are presented in Figure 1. 169
170
2.4. Sample preparation and extraction171
Samples of vitreous humor (100 µL), pericardial fluid (250 µL), blood (250 µL) and plasma (250 µL) 172
were prepared by the addition of 3 mL of 0.1 M phosphate buffer (pH 4.4) and 25 µL of  internal standard 173
solution (ethion) and were homogenised and centrifuged at 3000 rpm for 5 min. The aqueous phases were 174
added to the extraction cartridges, previously conditioned with 2 mL methanol and 2 mL of deionised 175
water. After the samples had passed through, the cartridges were washed sequentially with 2 mL 176
methanol 5% in deionised water and 2 mL of n-hexane. After drying under full vacuum the analytes were 177
eluted with a 2mL of a mixture of dichloromethane: isopropanol (75:25, v/v). The obtained extracts were 178
evaporated to dryness at 30 ºC under a gentle nitrogen stream, reconstituted with 50 µL of ethyl acetate 179
and transferred to autosampler vials to be injected a 2 µL aliquot  into the chromatographic system (GC-180
MS-EI).181
182
2.5. Validation procedure183
The described procedure was validated in terms of selectivity, linearity, limits of detection (LOD) and 184
quantitation (LLOQ), precision (intra-day and intermediate) and accuracy, extraction efficiency and 185
stability, according to international guidelines on bioanalytical method validation [30-39]. Validation data 186
were obtained by preparing quality control samples (QC) with drug-free matrices spiked with Salvinorin 187
A at three different concentrations  (low, medium and high).188
Selectivity was studied by analyzing ten pools from different sources of blank samples of each matrix: 189
vitreous humor, pericardial fluid, blood and plasma. They were checked for interferences at the retention 190
times and monitored ions for the analyte of interest and the internal standard. Also, they were analysed for 191
potential interferences from other substances, namely the most commonly encountered in routine analysis 192
in our laboratory (medical substances, pesticides and drugs of abuse, Table1). From each pool, two sets of 193
samples (n=10) were prepared into 10 mL glass tubes, and they were spiked with the same concentration 194
(100 ng/mL) of all the compounds presented in Table1; in addition, ten of these samples were further 195
spiked with Salvinorin A (10 ng/mL). It was obtained ten positive and ten negative samples which were 196
extracted and analysed by the aforementioned procedure. The criteria for identification the compounds 197
was established according to the recommendations of the World Anti-Doping Agency [39]. For 198
chromatography, the relative retention time of the substance must be within a 1% window, or 0.2 min in 199
absolute terms, from that of the same compound in a quality control sample prepared and analysed 200
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contemporaneously. Mass spectrometric identification in the SIM mode, must include at least three 201
diagnostic ions, and their relative intensities should not differ by more than a tolerated amount from those 202
generated by the same compound in a quality control sample prepared and analysed contemporaneously 203
(if the relative intensity of the ion is within a 25–50 % interval of the base peak in the control sample, a 204
maximum relative tolerance of ±20 % will be allowed for the same ion in the sample; if this intensity is 205
less than 25 % or higher than 50% in the control sample, then absolute tolerances of ±5 and ±10%, 206
respectively, will be allowed for the ion in the sample).207
In order to determine calibration curves, a linear range was established between 5 and 100 ng/mL (5, 8, 208
10, 15, 20, 30, 50, 60, 80, 100 ng/mL) for Salvinorin A, in each biological matrix. The calibration curves 209
were obtained by plotting the peak area ratio between Salvinorin A and ethion (IS) against theoretical 210
concentrations of the compound of interest. The criteria for acceptance included a R2 value of at least211
0.99, and the calibrator´s accuracy [mean relative error (bias) between measured and spiked 212
concentrations] within a ±15 % interval, except at the LLOQ, for which ±20 % was accepted.213
The potential for carryover was analyzed by injecting extracted blank, immediately after analysis of the 214
highest calibrator from each calibration curve.215
The LLOQ was defined as the minimum concentration of Salvinorin A that could be measured with 216
adequate precision (coefficient of variation <20 %) and accuracy (±20 %). The LOD was defined as the 217
lowest concentration yielding a signal-to-noise ratio of at least three. The intra-day precision was 218
determined by the analysis of five QC samples at each concentration level (low, medium and high) in219
each matrix on one day. It was characterized in terms of coefficient of variation (CV, %). The 220
intermediate precision and accuracy were assessed by the analysis of three QC samples at each 221
concentration level (low, medium and high) in each matrix on five different days. Accuracy was 222
calculated in terms of mean relative error (RE, %) between the measured and the spiked concentrations 223
for all QC samples; 15% was the limit of the acceptable variability for all concentrations.224
The extraction efficiency was evaluated by analysis of six QC samples at each concentration level (low, 225
medium and high) in each matrix, in which the IS was added after extraction. After that, the obtained 226
peak area ratios were compared to those obtained by spiking blank extracts with the same concentrations 227
of Salvinorin A (100 % recovery).228
To study the stability of Salvinorin A was used three QC samples at each concentration level (low, 229
medium and high). The stability of the processed samples was evaluated through analysis of the extracts 230
under the conditions of GC-MS analysis during 24h. For bench-top stability, samples of each matrix were 231
spiked and left at room temperature for 3 h, after that they were extracted and compared with freshly 232
spiked samples. To evaluate freeze/thaw cycles, the samples were spiked and stored 24 h at -15 ºC, after 233
this period, they were completely thawed and then frozen once again under the same conditions (a total of 234
three cycles was studied). Storage periods were one day, three days, and seven days, and the samples 235
were analysed after the third cycle. Comparisons between the means concentrations obtained in the 236
control and in the stability samples were made against an acceptance interval of 90-110 %. Furthermore, 237
the 90 % confidence interval has to be within 80-120 % of the control mean , [35-38].238
239
3. Results and discussion240
Page 7 of 20
Ac
ce
pte
d M
an
us
cri
pt
7
241
3.1. Selectivity242
No matrices interferences were observed at the retention times and at m/z values of the monitored ions, 243
by the analysis of the negative blank pools (see Figures 2 and 3). This indicates that neither endogenous 244
matrix constituents nor the substances in Table 1 interfere with the Salvinorin A or the IS. Furthermore, 245
the analytes were successfully identified in spiked samples. These results indicated that the described 246
method is selective for the determination of Salvinorin A in vitreous humor, pericardial fluid, blood, and 247
plasma samples.248
249
3.2. Linearity, limit of detection and limit of quantitation250
The linearity, LOD and LLOQ are shown in Table2. Linear calibration curves were obtained for all 251
matrices with R2 > 0.99. The calibrator’s accuracy was within the acceptance criteria.252
The analysis of extracted blank vitreous humor, pericardial fluid, blood and plasma, immediately after 253
injection of the highest calibrator from each calibration curve did not present any traces of carryover.254
The LOD and LLOQ were both determined at 5 ng/mL. These values are comparable to those obtained in 255
previous studies in plasma and blood [10,13,18], but were obtained with lower sample volumes (100 µL 256
of vitreous humor and 250 µL of pericardial fluid, whole blood and plasma), while plasma and blood 257
volumes of 1 and 0.5 mL were used in previous published works. It should be stated that these limits were 258
considered to be good values when compared with previously works, in which were required plasma and 259
blood volumes of 1 [10,13] and the 0.5 mL [18]. Regarding the results in vitreous humor and pericardial 260
fluid, it is not possible to compare limits, since the determination of Salvinorin A in these matrices is not 261
published yet.262
263
3.3. Intra-day precision, intermediate precision, and accuracy264
The results of the precision and accuracy are presented in Table 3 and 4. The intra-day and intermediate 265
precision were below 12 % at the studied concentrations for all matrices. The accuracy was ±9 % and thus266
within the acceptance criteria.267
268
3.4. Extraction efficiency269
Extraction efficiencies were between 79.65±4.62 and 99.09±4.68 as shown in Table 5. The reported 270
extraction efficiencies in human plasma [13] and in rhesus monkey plasma [10] ranged between 84.6±4.1 271
and 99.8 %, respectively. However, an adequate comparison with our results in vitreous humor and 272
pericardial fluid, it is not possible to do, since the determination of Salvinorin A in these matrices is not 273
published yet.274
                                                                                                                                                                                                                                                                                  275
3.5. Stability during bench-top and freeze/thaw cycles276
Stability of processed samples in the autosampler was guaranteed for 24h. The study also revealed that 277
Salvinorin A is stable in each matrix for 3 h at room temperature and for the freeze/thaw experiments the 278
acceptance criteria were fulfilled as shown in Table 6.279
280
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281
3.6. Applicability282
This study seems to us to be very important especially because the recent cases of people hospitalized 283
with severe psychotic disorders and with serious self-inflicted injuries that occurred during the 284
hallucinogenic episodes. On the other hand, several deaths associated with the consumption of salvia 285
divinorum, were reported in a certain area of Portugal. Despite this worrying situation is occurring, 286
unfortunately the forensic toxicological service did not have any request to analyse Salvinorin A in the 287
routine casework. However, we believe that this situation is due to lack of knowledge and information 288
about this new reality which makes forensic pathologists less prone to make the requests for the analysis289
of these new substances, as well as to collect the studied matrices. These situations can be an obstacle in 290
the development of new methodologies, so it is important to be prepared for the requests that will be 291
made in the future.292
Nevertheless, and even though no request to analyze the substance, the developed methodology is being 293
used routinely, in presumably intoxicated individuals with drugs of abuse. So far, fourteen blood samples 294
and three vitreous humor samples were analyzed for Salvinorin A, but none was positive. Taking into 295
account the low limits of the method, it is expected that the individuals didn’t consume salvia divinorum, 296
or there was a long period between the consumption and the samples collection.297
298
3.7. Conclusions299
According to the low volumes of samples used, and the low limits achieved using a single quadruple mass 300
spectrometer, which is available in most laboratories, the validated methodology proved to be sensitive 301
and specific for the analysis of Salvinorin A in conventional and unconventional biological matrices. 302
Furthermore, the results obtained indicate that the procedure is suitable for application in forensic 303
toxicology laboratories for the routine analysis of Salvinorin A. The small volumes required for the 304
validated procedure are extremely useful in situations when the available volume of the sample isscarce. 305
To the best of our knowledge this is the first procedure developed for the determination of Salvinorin A in 306
vitreous humor and pericardial fluid.307
After all, the development of the presented methodology seemed to be very timely, especially due to the 308
increase in the number of cases of intoxication with this type of substances registered in the emergencies309
of the Portuguese hospitals. So, it is very important that the pathologists are alerted to this new reality that 310
is the consumption of these kinds of drugs, mainly by young people. We believe that this procedure, in 311
the short term will be very useful for national and international application to authentic antemortem and 312
postmortem samples.313
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Figure captions392
Figure 1. Mass spectra and chemical structures of Salvinorin A and ethion.393
Figure 2. Ion chromatograms of blank and spiked samples (5 ng/mL) of VH (A, B) and PF (C, D) for 394
Salvinorin A at the monitored ions m/z 318, 359, 404 and 432 and at 231 for the internal standard 395
(ethion).396
Figure 3. Ion chromatograms of blank and spiked samples (5 ng/mL) of  PL (E, F) and BL (G, H) for 397
Salvinorin A at the monitored ions m/z  318, 359, 404, 432 and at 231 for the internal standard (ethion).398
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HIGHLIGHTS 
 
 First developed methodology  to determine Salvinorin A in VH and PF 
 VH and PF can be useful in postmortem cases when blood and urine are not available  
 Salvia divinorum currently has been associated to several cases of intoxication 
 Method suitable and quite opportune to clinical and forensic toxicology purposes 
 The method has good quantitation limits using low volumes of samples  
 
 
*Highlights (for review)
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Table 1. Substances tested for interferences. 
 
11-OH-THC Clobazam Fenarimol Mirtazapine 
6-acetylmorphine Clomipramine Fentanyl Morphine 
7-aminoclonazepam Clonazepam Fenthion Naproxen 
7-aminoflunitrazepam Clonazepam Flunitrazepam Nordazepam 
Acetaminophen Clorpromazine Fluoxetine Olanzapine 
Acetylsalicylic acid Clozapine Flurazepam Oxacarbamazepine 
Alprazolam Cocaine Foxyme Oxazepam 
Amitryptiline Codeine Imipramine Papaverine 
Amphetamine Cyalothrine Ketamine Paroxetine 
Atrazine Cyamemazine Ketoprofen Penconazole 
Atrazine Cyfluthrine Lamotrigine Phenacetin 
Azinphos-ethyl Cypermethrine Levomepromazine Phenobarbital 
Azinphos-methyl Deltamethrine Lidocaine Phenytoin 
Bendiocarb Demeton-S-methyl Lindane Propranolol 
Bentazone Demeton-S-methylsulphon Lorazepam Quetiapine 
Benzoylecgonine Desalquylflurazepam Maprotiline Quinalphos 
Bitertanol Diazepam MBDB Sertraline 
Bromazepam Diazinon MCPA Strychnine 
Bupirimate Dichlorvos MDA Sulphotep 
Caffeine Dimethoate MDEA Temazepam 
Carbamazepine Dinocap MDMA THC 
Chlorenvinphos DNOC Methadone THC-COOH 
Chlorpyrifos Ecgonine methyl esther Methamphetamine Topiramate 
Chlorpyrifos-methyl EDDP Mianserine Tramadol 
Citalopram Estazolam Midazolam Venlafaxine 
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Table 2. Calibration and limits (LOD/LLOQ) data (n=5).   
      
Biological 
Specimens 
Linear 
range 
(ng/mL) 
Linearity LOD/LLOQ 
Slope
(*)
 Intercept
(*)
 R
2(*)
 
(ng/mL) 
  
VH 5-100 8.8 E-03 ±1.1E-02 11.4 E-03 ±6.6 E-02 0.9972±1.9E-03 5 
PF 5-100 1.2 E-03 ±1.1E-03 1.5 E-03 ±5.7E-03 0.9980±0.7E-03 5 
BL 5-100 8.7 E-03 ±1.5E-02 26.1 E-03 ±3.3E-02 0.9973±2.3E-03 5 
PL 5-100 0.3 E-03 ±0.4E-04 0.7 E-03 ±0.9E-03 0.9973±1.3E-03 5 
 (*) 
Mean values ± standard deviation 
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Table 3. Intra-day precision (n=5).          
            
Biological 
Specimens 
Spiked Concentration (ng/mL) 
10 25  100 
Concentration 
Found (ng/mL) 
CV (%) RE (%) 
 Concentration 
Found (ng/mL) 
CV (%) RE (%) 
 Concentration 
Found (ng/mL) 
CV (%) RE (%) 
  
VH 10.2 8.8 1.9  25.1 11.7 0.2  93.9 6.3 -6.1 
PF 9.1 10.9 -9.3  25.4 5.7 1.7  97.8 5.4 -2.1 
BL 10.6 7.5 6.2  26.9 6.8 7.8  94.7 7.1 -5.3 
PL 10.0 1.7 -0.3  26.2 1.2 4.8  96.4 4.0 -3.6 
CV: coefficient of variation; RE: relative error [(concentration found-spiked concentration)/ spiked concentration x 100] 
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Table 4. Intermediate precision and trueness data (n=15).       
            
Biological 
Specimens 
Spiked Concentration (ng/mL) 
10 25   100 
Concentration 
Found (ng/mL) 
CV (%) RE (%) 
 Concentration 
Found (ng/mL) 
CV (%) RE (%) 
 Concentration 
Found (ng/mL) 
CV (%) RE (%) 
  
VH 10.1 3.8 0.5  24.3 6.6 -2.8  98.8 3.0 -1.2 
PF 10.4 11.2 3.9  25.7 5.1 2.7  102.3 6.8 2.3 
BL 10.0 2.3 0.4  24.9 4.6 -0.3  100.3 3.8 0.3 
PL 10.0 1.1 -0.1   25.6 1.9 2.2   100.8 3.5 0.8 
CV: coefficient of variation; RE: relative error [(concentration found-spiked concentration)/spiked concentration x 100] 
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Table 5. Extraction efficiency (%) (n=4). 
      
Biological 
Specimens 
 Concentration (ng/mL) 
         5 25 100 
VH 97.4±9.9 100.6±7.2 79.6±4.6 
PF 100.2±6.4 93.4±0.2 98.0±3.1 
BL 98.9±10.8 88.8±9.8 99.1±4.7 
PL 91.3±5.9 88.3±3.6 98.0±4.6 
Mean values ± standard deviation 
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Table 6. Freeze/thaw stability (%). 
Concentration 
(ng/mL) 
Freeze/thaw stability (7 days) 
VH PF BL PL 
% of 
controls 
90% CI 
% of 
controls 
90% CI 
% of 
controls 
90% CI 
% of 
controls 
90% CI 
10 105 85-116 103 99-107 103 99-108 100 93-106 
25 105 96-114 92 87-98 97 87-108 105 96-113 
100 104 95-113 84 81-87 86 85-87 100 95-105 
CI: Confidence Interval 
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